Latest News

Tiziana today announces its financial results for the year ended 31 December 2018.

Tiziana announced that it has submitted* an Investigational New Drug application ("IND") to the U.S. Food and Drug Administration (FDA)

Tiziana today announces that Riccardo Dalla-Favera MD has resigned from his role as Non-Executive Director of the Company. The Company is grateful to Dr Favera for his time, expertise and commitment to the Company.

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR
THE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014

Tiziana Life Sciences plc

("Tiziana" or the "Company")

Exercise of Warrants & Issue of Equity

New York/London, 11 December 2018 - Tiziana Life Sciences plc (Nasdaq: TLSA...

New York/London, 3 December 2018 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a biotechnology company focusing on the discovery and development of innovative therapeutics for inflammation and oncology indications, announces that patient enrollment in the ongoing Phase...

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR
THE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014

Tiziana Life Sciences plc
(“Tiziana” or the “Company”)

Tiziana Announces Initiation of Phase 1 Clinical Trial with Nasal Administration of Foralumab, a Fully Human Anti-Cluster Definition 3 Monoclonal...